Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | VHL | P40337 | 10/20 | 0.49 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.48 |
| ▸ | ELOC | Q15369 | 3/20 | 0.46 |
| ▸ | ELOB | Q15370 | 3/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15110596 | 0.89 | CYP1A2 (0.53) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL24838309 | 0.89 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL16266822 | 0.89 | CYP1A2 (0.53) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL18573054 | 0.88 | HDAC8 (0.54) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL24413712 | 0.87 | POLB (0.52) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL26655212 | 0.86 | VHL (0.52) | POLBCYP1A2CYP3A4CYP2C19VHL | |
| SCHEMBL24837775 | 0.86 | CYP1A2 (0.51) | POLBCYP1A2CYP3A4CYP2C19HDAC8 | |
| SCHEMBL1272783 | 0.85 | HDAC8 (0.49) | POLBCYP3A4CYP2C19HDAC8HTRA1 | |
| SCHEMBL1273269 | 0.85 | HDAC8 (0.49) | POLBCYP3A4CYP2C19HDAC8HTRA1 | |
| SCHEMBL25565558 | 0.84 | VHL (0.51) | POLBCYP3A4CYP2C19VHLELOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | POLB 4783/4885CYP1A2 4472/4885CYP3A4 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.